99% Purity Pharmaceutical Synthetic Peptides Goralatide, Seraspenide, AC-Sdkp Raw Material Treatment Inflammatory and Fibrotic Diseases

• Customization: Available
• CAS No.: 127103-11-1
• Formula: C20h33n5o9
• Model NO.: AC-Sdkp
• EINECS: 487.5
• Type: Synthesis Material Intermediates
• Appearance: Powder
• Quality: Refined
• Colour: White
• Content: Standard
• Usage: Laboratory Reagents
• Source: Dry Powder
• Habit Appellation: Fine Chemicals
• Application: Scientific Research
• Property: Protein and Peptide
• Classification: Research Peptides
• Note: No Tfa Salt
• From: Authoried Regluar Workshop
• Raw Powder: 1g/Bottle
• Attention: Research Use Only
• Transport Package: Customized
• Specification: 1G/Bottle 2mg/5mg/10mg per vial
• Trademark: Hoconbio
• Origin: China
• Production Capacity: 5kg Per Month

Product Description

99% Pure Synthetic Tetrapeptide Ac-SDKP Peptide Raw Powder Goralatide Seraspenide Peptide Powder Ac-SDKP For Anti-inflammatory And Antifibrotic

Product Name	Ac-SDKP
CAS NO.	N/A
Other name	goralatide / seraspenide
Appearance	White powder
Purity	98% HPLC
Application	Research peptides
Shelf Life	24 Months
Storage	Store at a temperature of 2-8 degrees, protected from light.

Ac-SDKP peptide (also known as seraspenide or goralatide)

The synthetic tetrapeptide Ac-SDKP, also called seraspenide or goralatide, has the chemical structure 1-(N2-(N-(N-acetyl-L-seryl)-L-alpha-aspartyl)-L-lysyl)-L-proline, the molecular formula C20H33N5O9, and a molecular weight of 487.50412 dalton. This tetrapeptide is involved in angiogenesis and the regulation of the immune response by blocking the proliferation of lymphocytes.

Ac-SDKP is a natural tetrapeptide with anti-inflammatory and antifibrotic properties. It has been widely distributed in mammalian organs, plasma, urine, and circulating mononuclear cells. The peptide is hydrolyzed by angiotensin-converting enzyme (ACE) and has a short half-life of 4.5 min in the circulation. Treatment with ACE inhibitors significantly increases plasma concentration of Ac-SDKP, and some of the ACE inhibitors protective effects were reported to be mediated by the increases in Ac-SDKP concentrations. In animal diseases with hypertension, as well as cardiovascular and kidney disease, Ac-SDKP reduces inflammatory cell infiltration and collagen deposition in the heart, kidney, lung, and liver. The peptide has potential applications in the treatment of various inflammatory and fibrotic diseases.